Biogen Posts Q3 Beat and Raises Guidance
Yahoo! Finance
Biogen (BIIB) reported stronger-than-expected Q3 results, topping both earnings and revenue estimates. The company also raised its FY2021 guidance above analyst expectations. However, shares of the multinational biotechnology company that develops, manufactures, and sells therapies for the treatment of neurodegenerative and neurological diseases were flat following the results. Markedly, adjusted earnings of $4.77 per share significantly beat analysts’ expectations of $4.11 per share. The compan
Continue Reading